Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin ... as a biosimilar under the name Insulin lispro Sanofi ...

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Insulin lispro, the rapid-acting component of Humalog Mix75/25, has been shown to be equipotent to Regular human insulin on a molar basis. Instruct patients on diet, exercise, blood or urine ...

Administering insulin can bring your blood sugar levels down. It’s important to talk with a doctor about how much rapid-acting insulin you should administer when your blood sugar is high.

In 1985, Novo Nordisk pioneered production of recombinant human insulin in yeast. In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering ...

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. The growth of the global rapid acting ...

Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said on Wednesday. The ...